A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia

被引：70

作者：

Yuan, Z. H. ^{[1
]}

Jiang, J. K. ^{[1
]}

Huang, W. D. ^{[1
]}

Pan, J. ^{[1
]}

Zhu, J. Y. ^{[1
]}

Wang, J. Z. ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Emergency, Hangzhou 310003, Zhejiang, Peoples R China

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2010年 / 17卷 / 06期

关键词：

Intracerebral hemorrhage; Randomized controlled trial; Recombinant activated factor VII; Meta-analysis; Thromboembolic adverse events; DEEP VENOUS THROMBOSIS; HIGH-DOSE FACTOR; HEMOSTATIC THERAPY; FATAL THROMBOSIS; RISK-FACTORS; PROGRESSION; PREDICTION; NOVOSEVEN; STRATEGY; EVENTS;

D O I：

10.1016/j.jocn.2009.11.020

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Hematoma growth is common in intracerebral hemorrhage (ICH) and is associated with a poor outcome for patients. To evaluate the efficacy and safety of recombinant activated factor VII (rFVIIa) used as a hemostatic agent in patients with ICH without hemophilia, we searched Medline, Scopus, the Cochrane Library, Clinicaltrials.gov and the Stroke Trials Directory. Five randomized controlled trials were selected for analysis. Although rFVIIa can reduce the change in ICH volume, there was no significant difference in mortality, modified Rankin Scale (mRS) score or extended Glasgow Outcome Scale (GOS-E) score in patients treated with rFVIIa or placebo. There was a significant increase in arterial thromboembolic adverse events (TAE) in patients treated with rFVIIa. There was an increase in deep vein thrombosis in patients with spontaneous ICH and traumatic ICH. In conclusion, the use of rFVIIa reduces the growth of the hematoma but does not improve patient survival or functional outcome after ICH; in addition, rFVIIa increases the incidence of arterial TAE. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：685 / 693

页数：9

共 36 条

[1]

Arkin S, 1998, HAEMOSTASIS, V28, P93

[2]

A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials [J].